Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

104 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients.
Cohen EE, Wu K, Hartford C, Kocherginsky M, Eaton KN, Zha Y, Nallari A, Maitland ML, Fox-Kay K, Moshier K, House L, Ramirez J, Undevia SD, Fleming GF, Gajewski TF, Ratain MJ. Cohen EE, et al. Among authors: hartford c. Clin Cancer Res. 2012 Sep 1;18(17):4785-93. doi: 10.1158/1078-0432.CCR-12-0110. Epub 2012 Aug 7. Clin Cancer Res. 2012. PMID: 22872575 Free PMC article. Clinical Trial.
Genetic variants in cytosolic 5'-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia.
Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, Ghodke Y, Gandhi V, Plunkett W, Dolan ME, Hartford C, Raimondi S, Campana D, Downing J, Rubnitz JE, Ribeiro RC, Lamba JK. Mitra AK, et al. Among authors: hartford c. J Pharmacol Exp Ther. 2011 Oct;339(1):9-23. doi: 10.1124/jpet.111.182873. Epub 2011 Jun 28. J Pharmacol Exp Ther. 2011. PMID: 21712425 Free PMC article.
Comprehensive genetic analysis of cytarabine sensitivity in a cell-based model identifies polymorphisms associated with outcome in AML patients.
Gamazon ER, Lamba JK, Pounds S, Stark AL, Wheeler HE, Cao X, Im HK, Mitra AK, Rubnitz JE, Ribeiro RC, Raimondi S, Campana D, Crews KR, Wong SS, Welsh M, Hulur I, Gorsic L, Hartford CM, Zhang W, Cox NJ, Dolan ME. Gamazon ER, et al. Among authors: hartford cm. Blood. 2013 May 23;121(21):4366-76. doi: 10.1182/blood-2012-10-464149. Epub 2013 Mar 28. Blood. 2013. PMID: 23538338 Free PMC article. Clinical Trial.
Phase I study of the safety and pharmacokinetics of plerixafor in children undergoing a second allogeneic hematopoietic stem cell transplantation for relapsed or refractory leukemia.
Srinivasan A, Panetta JC, Cross SJ, Pillai A, Triplett BM, Shook DR, Dallas MH, Hartford C, Sunkara A, Kang G, Jacobsen J, Choi J, Leung W. Srinivasan A, et al. Among authors: hartford c. Biol Blood Marrow Transplant. 2014 Aug;20(8):1224-8. doi: 10.1016/j.bbmt.2014.04.020. Epub 2014 Apr 23. Biol Blood Marrow Transplant. 2014. PMID: 24769325 Free PMC article. Clinical Trial.
Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia.
Leung W, Pui CH, Coustan-Smith E, Yang J, Pei D, Gan K, Srinivasan A, Hartford C, Triplett BM, Dallas M, Pillai A, Shook D, Rubnitz JE, Sandlund JT, Jeha S, Inaba H, Ribeiro RC, Handgretinger R, Laver JH, Campana D. Leung W, et al. Among authors: hartford c. Blood. 2012 Jul 12;120(2):468-72. doi: 10.1182/blood-2012-02-409813. Epub 2012 Apr 19. Blood. 2012. PMID: 22517895 Free PMC article.
104 results